These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22223606)

  • 1. Causes of alternative pathway dysregulation in dense deposit disease.
    Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
    Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
    Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
    Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2019; 10():1350. PubMed ID: 31263464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
    Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
    Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
    Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
    Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-factor B autoantibody in dense deposit disease.
    Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
    Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
    Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
    J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
    Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.